BLX-301

BLX-301 is an anti-CD20 antibody that we are optimizing for the treatment of non-Hodgkin’s B-cell lymphoma. BLX-301 is based on the capability of the LEX System to optimize a key component of monoclonal antibodies, the sugar chain, or glycosylation structure, to increase their potency and efficacy. In May 2007, we announced preclinical results highlighting the ability of the LEX System to produce an anti-CD20 antibody with enhanced cytotoxicity and potentially lower side effects than Rituxan, the top selling treatment for non-Hodgkin’s B-cell lymphoma, which is also used to treat rheumatoid arthritis. BLX-301 is currently in preclinical development, and we expect to commence a Phase 1 clinical trial in non-Hodgkin’s B-cell lymphoma patients in 2009.

Return to top